FMP
Nautilus Biotechnology, Inc.
NAUT
NASDAQ
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
2.73 USD
-0.03 (-1.1%)
About
ceo
Mr. Sujal M. Patel
sector
Healthcare
industry
Biotechnology
website
https://www.nautilus.bio
exchange
NASDAQ
Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
CIK
0001808805
ISIN
US63909J1088
CUSIP
63909J108
Address
2701 Eastlake Avenue East
Phone
206 333 2001
Country
US
Employee
163
IPO Date
Aug 7, 2020
Key Executives
